Sagimet Biosciences (SGMT) Amortizatization of Intangibles (2022 - 2026)
Sagimet Biosciences (SGMT) recorded quarterly Amortizatization of Intangibles of $140000.0 in Q1 2026, up 146.67% quarter-over-quarter from -$300000.0 in Q4 2025, and down 73.83% on a YoY basis from $535000.0 in Q1 2025.
Sagimet Biosciences (SGMT) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $140000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 73.83% year-over-year to $140000.0; the TTM figure through Mar 2026 stood at -$6000.0 (down 100.38% YoY), while the FY2025 annual figure was $389000.0, down 68.95% from the prior year.
- Amortizatization of Intangibles was $140000.0 for Q1 2026 at Sagimet Biosciences, up from -$300000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $535000.0 in Q1 2025 to a low of -$300000.0 in Q4 2025.
- Historically, Amortizatization of Intangibles has averaged $142142.9 across 5 years, with a median of $85500.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles soared 11825.0% in 2024, then tumbled 635.71% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $83000.0 in 2022, then slumped by 102.41% to -$2000.0 in 2023, then jumped by 2900.0% to $56000.0 in 2024, then sank by 635.71% to -$300000.0 in 2025, then jumped by 146.67% to $140000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $140000.0 (Q1 2026), -$300000.0 (Q4 2025), and -$72000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Sagimet Biosciences | 211.96 Mn | 211.96 Mn | - | 140,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 140,000.00 |
| Mar 31, 2026 | 140,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | -72,000.00 |
| Sep 30, 2025 | -72,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 535,000.00 |
| Mar 31, 2025 | 535,000.00 |
| Dec 31, 2024 | 56,000.00 |
| Dec 31, 2024 | 56,000.00 |
| Sep 30, 2024 | 527,000.00 |
| Sep 30, 2024 | 527,000.00 |
| Jun 30, 2024 | 477,000.00 |
| Jun 30, 2024 | 477,000.00 |
| Mar 31, 2024 | 193,000.00 |
| Mar 31, 2024 | 193,000.00 |
| Dec 31, 2023 | -2,000.00 |
| Dec 31, 2023 | -2,000.00 |